PanGenomic Health Inc - PanGenomic Health Announces Changes to Board of Directors
PR Newswire
LONDON, United Kingdom, February 16
Vancouver, British Columbia, Canada, 16 February 2024 - PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) (AQSE: NARA) announces changes to its board of directors.
The Company announces the resignation of Vincent Lum as a director of the Company. Mr. Lum, the previous CEO and a co-founder of PanGenomic Health, will continue to serve as the CEO, President, Executive Chair and a director of the Company's subsidiary, MUJN Diagnostics Inc.
The Company is pleased to announce the appointment of Francisco Kent Carasquero as a director of the Company. Mr. Carasquero previously served as the VP Finance and a director of the Company and has acted as a corporate finance consultant to the Company since its listing on the Canadian Securities Exchange.
Mr. Carasquero owns 454,978 common shares in the issued share capital of the Company.
Current Directorships | Former Directorships and/or partnerships (within the last five years) |
Fintechwerx International Software Services Inc. (CSE:WERX) | Zetta Capital Corp. (now PanGenomic Health Inc.) CPT Secure Inc. Looking Glass Media Limited ETC3 Holdings Ltd. |
There is no further information regarding Mr. Carasquero that is required to be disclosed pursuant to Rule 4.9 of the AQSE Growth Market Access Rulebook.
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.
About PanGenomic Health
PanGenomic Health is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments. The Company's initial focus is to support mental health. Registered as a British Columbia benefit company, PanGenomic Health's mission is to promote and improve the health and wellness of people and society by providing a technology platform that identifies plant-based solutions tailored to the health profile of each individual.
For more information, please contact:
Jerry Lai, Investor Relations Novum Securities Limited, AQSE Corporate Adviser
PanGenomic Health Inc. David Coffman/ George Duxberry
+1 778 743 4642 +44 (0)207 399 9400
ir@pangenomic.com
This news release includes certain statements that may be deemed "forward-looking statements", including statements respecting the services to be provided by PanGenomic Health and the consideration to be paid to PanGenomic Health. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "would", "project", "should", "believe" and similar expressions are intended to identify forward looking statements. Although PanGenomic Health believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because PanGenomic Health can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in PanGenomic Health's disclosure documents which can be found under PanGenomic Health's profile on www.sedarplus.ca.
The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.
